MRTX - Mirati Therapeutics Inc Stock Price, Fair Value and News

58.70USD Market Closed

Market Summary

USD58.70

Market Closed

MRTX Stock Price

View Fullscreen

MRTX RSI Chart

MRTX Valuation

Market Cap

4.1B

Price/Earnings (Trailing)

-5.67

Price/Sales (Trailing)

107.82

EV/EBITDA

-5.27

Price/Free Cashflow

-6.91

MRTX Price/Sales (Trailing)

MRTX Profitability

EBT Margin

-1929.91%

Return on Equity

-76.69%

Return on Assets

-64.25%

Free Cashflow Yield

-14.47%

MRTX Fundamentals

MRTX Revenue

Revenue (TTM)

38.2M

MRTX Earnings

Earnings (TTM)

-725.9M

Breaking Down MRTX Revenue

Last 7 days

-0.8%

Last 30 days

1.8%

Last 90 days

5.6%

Trailing 12 Months

36.5%

How does MRTX drawdown profile look like?

MRTX Financial Health

Current Ratio

7.54

MRTX Investor Care

Shares Dilution (1Y)

21.81%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	18.9M	27.2M	38.2M	0
2022	67.0M	48.8M	30.6M	12.4M
2021	0	0	49.3M	85.2M
2020	5.9M	8.4M	10.9M	13.4M
2019	4.7M	5.3M	6.3M	3.3M
2018	5.6M	8.0M	10.5M	12.9M
2011	0	0	0	3.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Mirati Therapeutics Inc

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

CEO	Dr. Charles M. Baum M.D., Ph.D.
WEBSITE	mirati.com
INDUSTRY	Biotechnology
EMPLOYEES	587

Mirati Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Mirati Therapeutics Inc? What does MRTX stand for in stocks?

MRTX is the stock ticker symbol of Mirati Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Mirati Therapeutics Inc (MRTX)?

As of Tue Jan 23 2024, market cap of Mirati Therapeutics Inc is 4.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRTX stock?

You can check MRTX's fair value in chart for subscribers.

Is Mirati Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether MRTX is over valued or under valued. Whether Mirati Therapeutics Inc is cheap or expensive depends on the assumptions which impact Mirati Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRTX.

What is Mirati Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Jan 23 2024, MRTX's PE ratio (Price to Earnings) is -5.67 and Price to Sales (PS) ratio is 107.82. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Mirati Therapeutics Inc's stock?

In the past 10 years, Mirati Therapeutics Inc has provided 0.103 (multiply by 100 for percentage) rate of return.